46 results about "Galactomyces candidum" patented technology

The present invention relates to a composition comprising IgY antibodies against at least two different fungi, the use of the composition for the preparation of a pharmaceutical especially for prophylaxis and / or therapy of all kinds of fungal infections, such as conditions caused by organisms belonging to the Candida genus or Aspergillus genus, especially of fungi that are less sensitive to antimycotica and a diagnotstic method using the IgY antibodies. Further it relates to immunisation of birds with a combination of at least two different species of fungi to the Candida genus or Aspergillus genus and a diagnostic method for fungi. It also relates to relates to a novel method for treatment and / or prophylaxis of fungal infections, especially infections by fungi which have lowered sensitivity or resistance to antimycotics. The method is both safe and effective. This is achieved by using IgY directed against fungi, in particular against Candida species, which have a lowered sensitivity or resistance against antimycotics. The specific IgY has been obtained by hyper immunising birds with one or several fungi as antigen in order to stimulate the production of immune globulins (IgY) against such fungi. The present invention also relates to a pharmaceutical product from eggs of birds containing immune globulin or a fragment thereof, which can be combined with other preparations, nutritients or pharmaceuticals for simultaneous, separate or sequential use in the prophylaxis or therapy of gastrointestinal infections in newborn infants.

A method for producing xylitol by fermentation of lignocellulosic hydrolysates without detoxification is provided. By using the originally isolated yeast Candida sp., xylose can be effectively converted into xylitol. The invention also provides the Candida strain having high furfural tolerance, and is capable to produce xylitol from various types of non-detoxified lignocellulosic hydrolysates, in which the overall utilization of xylose in hydrolysate can reach over 95%.

The invention discloses a strain of Lactobacillus rhamnosus. The strain with the preservation name of Lactobacillus rhamnosus B156, was preserved in China General Microbiological Culture Collection Center on September 10, 2018, and the preservation number is CGMCC No.16453. The invention further discloses application of the Lactobacillus rhamnosus in preparing medicines inhibiting Candida albicansand Vibrio vulnificus, health care products or common food, and in preparing a preparation prolonging survival time of bagging planting of Anoectochilus roxburghii tissue culture seedlings. The Lactobacillus rhamnosus B156 provided by the invention and fermented yoghurt prepared by the strain can remarkably inhibit the growth of the Candida albicans; the strain can remarkably improve the survivalrate of zebra fish attacked by the Vibrio vulnificus, and remarkably prolong the survival time of the bagging planting of the Anoectochilus roxburghii tissue culture seedlings. Therefore, the Lactobacillus rhamnosus B156 provided by the invention has relatively high social application value.

The present invention relates to Leuconostoc citreum CJGN34 KCTC 10974BP lactic acid bacteria, fermented foods including kimchi manufactured using the lactic acid bacteria as a starter, and lactic acid bacteria composition comprising of the lactic acid bacteria. The novel Leuconostoc citreum CJGN34 of the present invention enhances the general taste quality of kimchi; increases the intrinsic complex sour taste and carbonated taste of kimchi manufactured by traditional manufacturing method in wintertime; and regularly sustains the fermentation quality during the year; particularly, has an effect for controlling the deterioration of fermentation quality in the summer in which the taste quality deteriorates. Thus, the lactic acid bacteria of the present invention can be used as a starter in fermented foods including kimchi, or as a drug medicine in the form of a tablet or capsule mixed with carriers or additives, or a s probiotics for foods; or applied in cosmetic ingredients by mixing in a certain amount. Therefore, the lactic acid bacteria of the present invention can be used in a manner commonly applied in various fields of technology such as medicine, food, feed, cosmetics or the like.

The invention discloses a gene chip for detecting 15 clinical common pathogenic microorganisms. The gene chip comprises specific detection probes fixed on a solid phase vector, wherein the probes are designed for 16SrRNA gene and ITS gene sequences of staphylococcus aureus, klebsiella pneumoniae, pseudomonas aeruginosa, proteus mirabilis, Escherichia coli, shigella, enterobacter aerogenes, pseudomonas fluorescens, candida albicans, candida glabrata, candida tropicalis, candida parapsilosis, aspergillus terreus, aspergillus flavus and rhizopus oryzae, and screened and verified by repeated tests, and have high hybridization specificity and accuracy. The chip provided by the invention ensures simple detection operations and relatively lower cost, saves time, is applied to the screening of the clinical common pathogenic microorganisms, the early rapid diagnosis of critical patients and the diagnosis of suddenly occurring infection event pathogens and favorable for clinically rapidly diagnosing infection sources and functions in the early detection and early diagnosis of clinical diseases.

An animal model infected by candida albicans where the primary infection is the local abscess in the ear and is accompanied by the infection of candida albicans in all organs. The method is to inject the candida albicans into the subcutaneous of the ear of a rabbit and the concentration of the candida albicans is 1X105 / ml-1X1010 / ml. By doing so, not only the local abscess in the ear is formed, but all organs are infected through blood circulation. In this invention, the model is easy to obtain; the local abscess in the ear can be observed conveniently; the two ears can be compared and the infection of all the organs can be detected at the same time. Thus, the present invention provides a simple and convenient animal model for developing new methods and medicines for the treatment of candida albicans.

The invention relates to a microbial agent for decomposing TVOC (total volatile organic compound). Strains are added into fermentation liquid base solution and fermented to obtain the microbial agentand include rhodopseudomonas, rhodospirillum, lactobacillus, candida, nitrate bacteria, streptomyces and chromatium, and the total bacteria density of the microbial agent is (1-10)*10<8> bacteria / L. The microbial agent can be directly sprayed into air to treat the TVOC after dilution. Harmful substances in the TVOC can be purified, decomposed and transferred into harmless and odorless substances.Pathogenic bacteria such as pathogenic escherichia coli, mycetes, staphylococcus aureus and candida albicans can be removed, air quality is thoroughly improved, and fitness is protected.

The invention relates to a strain of Galactomyces candidum CM1 capable of degrading cephalosporin antibiotics, belonging to the technical field of microorganisms. The strain was deposited in the General Microorganism Center of China Committee for Microorganism Culture Collection on November 10, 2017, with the preservation number CGMCC NO.14633. The strain is easy to cultivate, grows fast, has the function of degrading cephalosporin antibiotics, and can degrade and eliminate the toxicity and inhibitory effect of cephalosporin antibiotics on Gram-positive bacteria. It can be applied to the production of bacterial agents, to deal with the waste of cephalosporin antibiotic production enterprises and the residual cephalosporin antibiotics in the environment, and to reduce the harm of cephalosporin antibiotics to the environment and human beings.